Sign In
Buy ORMP
$3.65
+0.0500 (+1.39%)
At Close: Jun 03, 2026
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
03:31pm, Friday, 22'nd May 2026
Oramed Pharmaceuticals is downgraded from 'Strong Buy' to 'Hold' due to the failed phase 3 trial for ORMD-0801 in Type 2 Diabetes. ORMP pivots to target a subset of T2D patients and transfers its POD
Reviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & Akanda (NASDAQ:AKAN)
01:55am, Sunday, 05'th Apr 2026
Akanda (NASDAQ: AKAN - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two c
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
08:00am, Friday, 13'th Mar 2026
Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while
Head to Head Review: GN Store Nord (OTCMKTS:GNNDY) and Oramed Pharmaceuticals (NASDAQ:ORMP)
02:08am, Friday, 06'th Mar 2026
Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and GN Store Nord (OTCMKTS:GNNDY - Get Free Report) are both medical companies, but which is the better business? We will compare the two busine
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average – Here’s Why
04:56am, Tuesday, 24'th Feb 2026
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP - Get Free Report)'s stock price passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.26 and traded as
Comparing QuidelOrtho (NASDAQ:QDEL) & Oramed Pharmaceuticals (NASDAQ:ORMP)
02:08am, Friday, 13'th Feb 2026
QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving Average – Time to Sell?
04:58am, Tuesday, 27'th Jan 2026
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.03 and traded a
Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intend
Oramed and Lifeward Announce Strategic Transaction
07:58am, Tuesday, 13'th Jan 2026
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
08:55am, Wednesday, 07'th Jan 2026
Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed
Reviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & GE HealthCare Technologies (NASDAQ:GEHC)
05:22am, Sunday, 04'th Jan 2026
Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and GE HealthCare Technologies (NASDAQ: GEHC - Get Free Report) are both medical companies, but which is the superior business? We will contrast
Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback
02:28pm, Wednesday, 24'th Dec 2025
Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 6
Oramed Reports Fiscal Third Quarter 2025 Financial Results
08:56am, Monday, 17'th Nov 2025
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
08:50am, Monday, 17'th Nov 2025
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 20
Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company Accelerating Growth Through Strategic Partner
